^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma

Published date:
01/24/2021
Excerpt:
...to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro...Overexpression of BCL-2 and MCL-1 was noted in gastric cancer tissues (GC).AT-101 induced apoptosis, reduced proliferation and tumour sphere formation in MCL-1/BCL-2 high GC cells.
DOI:
10.1136/gutjnl-2020-321175